---
title: "Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285420620.md"
description: "TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on Summit Therapeutics (SMMT) due to a stable long-term sales outlook and an attractive risk/reward profile. Despite raising future operating expense projections, he maintained sales expectations, reflecting confidence in the company's growth potential. Encouraged by management's commentary and clinical updates, Van Buren believes the stock remains a solid investment. H.C. Wainwright also supports this view with a Buy rating and a $23.00 price target."
datetime: "2026-05-06T17:25:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285420620.md)
  - [en](https://longbridge.com/en/news/285420620.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285420620.md)
---

# Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on SMMT stock, giving a Buy rating on May 4.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tyler Van Buren has given his Buy rating due to a combination of factors, including confidence in Summit Therapeutics’ long-term revenue outlook despite recent adjustments. Following the Q1 report, he modestly raised operating expense projections for 2026 and beyond, but importantly left both annual and peak sales expectations intact, signaling sustained conviction in the company’s growth potential.

He also appears encouraged by management’s post-earnings commentary, particularly around the HARMONi-3 progression-free survival interim update, which supports the underlying clinical and commercial thesis. Overall, the combination of stable revenue assumptions, only incremental cost adjustments, and continued positive signals from the pipeline underpins his view that the risk/reward profile remains attractive for investors at current levels.

In another report released on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)